SET Protein in Cancer: A Potential Therapeutic Target

2021 ◽  
Vol 21 ◽  
Author(s):  
Xinjie Liang ◽  
Xuefei Bao ◽  
Guoliang Chen
Keyword(s):  
Drug Resistance ◽  
Clinical Trials ◽  
Cancer Therapy ◽  
Tumor Cells ◽  
Strong Correlation ◽  
Therapeutic Target ◽  
Poor Prognosis ◽  
Therapeutic Options ◽  
Potential Therapeutic Target ◽  
Bona Fide

: SET protein is a multi-functional oncoprotein that is ubiquitously expressed in most tumor cells. Dysregulation of SET has been associated with many types of cancer. Due to ever-accumulating evidence of its strong correlation with both poor prognosis and drug resistance, the targeting of SET is starting to be explored. SET is currently regarded as a potential target for cancer therapy, and several inhibitors are being developed for clinical trials. In this review, the physiological and pathological functions of SET, as well as its antagonists, will be discussed along with the prospects and challenges involved with translating SET inhibitors into bona fide therapeutic options.

Hybrid Compounds & Oxidative Stress Induced Apoptosis in Cancer Therapy

2020 ◽  
Vol 27 (13) ◽  
pp. 2118-2132 ◽  
Author(s):  
Aysegul Hanikoglu ◽  
Hakan Ozben ◽  
Ferhat Hanikoglu ◽  
Tomris Ozben
Keyword(s):  
Oxidative Stress ◽  
Drug Resistance ◽  
Side Effects ◽  
Cancer Therapy ◽  
Tumor Cells ◽  
Anticancer Drugs ◽  
Chemotherapeutic Agents ◽  
Oxidation Reactions ◽  
Hybrid Compounds ◽  
Induced Apoptosis

: Elevated Reactive Oxygen Species (ROS) generated by the conventional cancer therapies and the endogenous production of ROS have been observed in various types of cancers. In contrast to the harmful effects of oxidative stress in different pathologies other than cancer, ROS can speed anti-tumorigenic signaling and cause apoptosis of tumor cells via oxidative stress as demonstrated in several studies. The primary actions of antioxidants in cells are to provide a redox balance between reduction-oxidation reactions. Antioxidants in tumor cells can scavenge excess ROS, causing resistance to ROS induced apoptosis. Various chemotherapeutic drugs, in their clinical use, have evoked drug resistance and serious side effects. Consequently, drugs having single-targets are not able to provide an effective cancer therapy. Recently, developed hybrid anticancer drugs promise great therapeutic advantages due to their capacity to overcome the limitations encountered with conventional chemotherapeutic agents. Hybrid compounds have advantages in comparison to the single cancer drugs which have usually low solubility, adverse side effects, and drug resistance. This review addresses two important treatments strategies in cancer therapy: oxidative stress induced apoptosis and hybrid anticancer drugs.

scholarly journals S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia

2012 ◽  
Vol 103 (12) ◽  
pp. 2056-2063 ◽  
Author(s):  
Ling Liu ◽  
Lei Fan ◽  
Cheng Fang ◽  
Zhi-Jian Zou ◽  
Shu Yang ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Therapeutic Target ◽  
Poor Prognosis ◽  
Lymphocytic Leukemia ◽  
Potential Therapeutic Target

scholarly journals TWIST1 is a molecular marker for a poor prognosis in oral cancer and represents a potential therapeutic target

Cancer ◽  
2013 ◽  
Vol 120 (3) ◽  
pp. 352-362 ◽  
Author(s):  
Sabrina Daniela da Silva ◽  
Moulay A. Alaoui-Jamali ◽  
Fernando Augusto Soares ◽  
Dirce Maria Carraro ◽  
Helena Paula Brentani ◽  
...  
Keyword(s):  
Oral Cancer ◽  
Molecular Marker ◽  
Therapeutic Target ◽  
Poor Prognosis ◽  
Potential Therapeutic Target

scholarly journals MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy

Biomolecules ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. 1040 ◽  
Author(s):  
Milad Ashrafizadeh ◽  
Hui Li Ang ◽  
Ebrahim Rahmani Moghadam ◽  
Shima Mohammadi ◽  
Vahideh Zarrin ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Cancer Therapy ◽  
Signaling Pathways ◽  
Tumor Cells ◽  
Cancer Progression ◽  
Epithelial Mesenchymal Transition ◽  
Migration And Invasion ◽  
Circular Rnas ◽  
Mesenchymal Transition ◽  
The Impact

Molecular signaling pathways involved in cancer have been intensively studied due to their crucial role in cancer cell growth and dissemination. Among them, zinc finger E-box binding homeobox-1 (ZEB1) and -2 (ZEB2) are molecules that play vital roles in signaling pathways to ensure the survival of tumor cells, particularly through enhancing cell proliferation, promoting cell migration and invasion, and triggering drug resistance. Importantly, ZEB proteins are regulated by microRNAs (miRs). In this review, we demonstrate the impact that miRs have on cancer therapy, through their targeting of ZEB proteins. MiRs are able to act as onco-suppressor factors and inhibit the malignancy of tumor cells through ZEB1/2 down-regulation. This can lead to an inhibition of epithelial-mesenchymal transition (EMT) mechanism, therefore reducing metastasis. Additionally, miRs are able to inhibit ZEB1/2-mediated drug resistance and immunosuppression. Additionally, we explore the upstream modulators of miRs such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), as these regulators can influence the inhibitory effect of miRs on ZEB proteins and cancer progression.

scholarly journals Mitochondrial TXNRD3 confers drug resistance via redox-mediated mechanism and is a potential therapeutic target in vivo

Redox Biology ◽  
2020 ◽  
Vol 36 ◽  
pp. 101652 ◽  
Author(s):  
Xiaoxia Liu ◽  
Yanyu Zhang ◽  
Wenhua Lu ◽  
Yi Han ◽  
Jing Yang ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Therapeutic Target ◽  
Potential Therapeutic Target

MicroRNA-216a: a potential therapeutic target for drug resistance and recurrent liver cancer

2013 ◽  
Vol 12 (6) ◽  
pp. 661 ◽  
Author(s):  
Zhao-Lin Chen ◽  
Tao-Tao Ma ◽  
Cheng Huang ◽  
Tao Xu ◽  
Ting-Ting Hu ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Liver Cancer ◽  
Therapeutic Target ◽  
Potential Therapeutic Target

scholarly journals Discovery of Oxazolidinone-Based Heterocycles as Subtype Selective Sigma-2 Ligands

2021 ◽  
Author(s):  
Benjamin E Blass ◽  
Richie Rashmin Bhandare ◽  
Daniel J. Canney
Keyword(s):  
Therapeutic Target ◽  
Amyloid Plaques ◽  
Therapeutic Options ◽  
Potential Therapeutic Target ◽  
Root Cause ◽  
Amyloid Hypothesis ◽  
Medical Need ◽  
The Us ◽  
Subtype Selective ◽  
The Brain

Abstract Alzheimer’s disease is a major, unmet medical need that impacts 6 million people in the US alone. Therapeutic options are limited, and the root cause of this condition remains unclear. The Amyloid Hypothesis has been proposed as a means of explaining the formation of amyloid plaques in the brain of patient. The sigma-2 receptor was recently identified as a potential therapeutic target capable of arresting the formation of amyloid plaques. Herein, we report the identification of a series of novel, functionalized oxazolidin-2-ones sigma-2 ligands.

Vitamin D/VDR in acute kidney injury: a potential therapeutic target

2020 ◽  
Vol 27 ◽  
Author(s):  
Siqing Jiang ◽  
Lihua Huang ◽  
Wei Zhang ◽  
Hao Zhang
Keyword(s):  
Vitamin D ◽  
Acute Kidney Injury ◽  
Therapeutic Target ◽  
Poor Prognosis ◽  
Therapeutic Potential ◽  
Kidney Injury ◽  
Potential Therapeutic Target ◽  
Promising Therapeutic Target ◽  
Incidence And Mortality

: Despite many strategies and parameters used in clinical practice, the incidence and mortality of acute kidney injury (AKI) are still high with poor prognosis. With the development of molecular biology, the role of vitamin D and vitamin D receptor (VDR) in AKI is drawing increasing attention. Accumulated researches have suggested that Vitamin D deficiency is a risk factor of both clinical and experimental AKI, and vitamin D/VDR could be a promising therapeutic target against AKI. However, more qualitative clinical researches are needed to provide stronger evidence for clinical application of vitamin D and VDR agonists in the future. Issues like the route and dosage of administration also await more attention. The present review aims to summarize the current works on the role of vitamin D/VDR in AKI and try to provide some new insight of its therapeutic potential.

Sign in / Sign up

Export Citation Format

Share Document